drugset / Trial / NCT05805098
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
NaSingle-groupOpen-labelTreatment
Summary
This study aims to evaluate the efficacy and safety of venetoclax combined with homoharringtonine and cytarabine in the treatment of newly diagnosed acute myeloid leukemia.
Timeline
- Start
- 2023-03-01
- Primary completion
- 2025-03-01
- Completion
- 2028-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Homoharringtonine | Small molecule | 1 mg/m2 | Intravenous |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |